Neo-intimal hyperplasia, diabetes and endovascular injury

Cardiovascular Journal of Africa

Volumn 23, Issue 9, 2012, Pages 507-511

  Kruger, Deirdré ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Critical limb ischaemia; Diabetes; Endovascular stenting; Neo intimal hyperplasia; Vascular progenitor cells

Indexed keywords

FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; SOMATOMEDIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ARTERY INTIMA PROLIFERATION; BLOOD VESSEL INJURY; CELL DIFFERENTIATION; DIABETES MELLITUS; HUMAN; RESTENOSIS; REVIEW; STEM CELL; TIBIAL ARTERY;

AFRICA; ANIMALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; DIABETIC FOOT; HUMANS; HYPERPLASIA; PERIPHERAL ARTERIAL DISEASE; POSTOPERATIVE COMPLICATIONS; PREVALENCE; REOPERATION; RISK; STENTS; TUNICA INTIMA; VASCULAR SYSTEM INJURIES;

EID: 84869469349     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2012-019     Document Type: Review

References (58)

1. World Health Organization. Diabetes. 2011; Available at: http:// www.who.int/mediacentre/factsheets/fs312/en/index.html#. Accessed 5 April, 2011.
2. Kugler CF, Rudofsky G. The challenges of treating peripheral arterial disease. Vasc Med 2003; 8(2): 109-114. (Pubitemid 37168252)
3. Beckman JA, Creager MA, Libby P. Diabetes and Atherosclerosis. J Am Med Assoc 2002; 287(19): 2570-2581. DOI: 10.1001/jama.287.19.2570.
4. Dick F, Diehm N, Galimanis A, Husmann M, Schmidli J, Baumgartner I. Surgical or endovascular revascularization in patients with critical limb ischemia: Influence of diabetes mellitus on clinical outcome. J Vasc Surg 2007; 45(4): 751-761. DOI: 10.1016/j.jvs.2006.12.022. (Pubitemid 46483943)
5. Jude EB, Oyibo SO, Chalmers N, Boulton AJM. Peripheral arterial disease in diabetic and nondiabetic patients. Diabetes Care 2001; 24(8): 1433-1437. DOI: 10.2337/diacare.24.8.1433.
6. Virkkunen J, Heikkinen M, Lepäntalo M, Metsänoja R, Salenius J. Diabetes as an independent risk factor for early postoperative complications in critical limb ischemia. J Vasc Surg 2004; 40(4): 761-767. DOI: 10.1016/j.jvs.2004.07.040. (Pubitemid 39311645)
7. Graziani L, Piaggesi A. Indications and clinical outcomes for below knee endovascular therapy: review article. Catheter Cardiovasc Interv 2010; 75(3): 433-443. DOI: 10.1002/ccd.22287.
8. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994; 1(4): 333-339.
9. Bakken AM, Palchik E, Hart JP, Rhodes JM, Saad WE, Davies MG. Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions. J Vasc Surg 2007; 46(5): 946-958. DOI: 10.1016/j.jvs.2007.06.047.
10. Allie DE, Hebert CJ, Lirtzman MD, Wyatt CH, Keller VA, Khan MH, et al. Critical limb ischemia: a global epidemic. A critical analysis of current treatment unmasks the clinical and economic costs of CLI. EuroIntervention 2005; 1(1): 75-84.
11. Klevsgard R, Risberg BO, Thomsen MB, Hallberg IR. A 1-year follow-up quality of life study after hemodynamically successful or unsuccessful surgical revascularization of lower limb ischemia. J Vasc Surg 2001; 33(1): 114-122. DOI: 10.1067/mva.2001.109769. (Pubitemid 32109614)
12. DeRubertis BG, Faries PL, McKinsey JF, Chaer RA, Pierce M, Karwowski J, et al. Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions. Ann Surg 2007; 246(3): 415-22; discussion 422-4. DOI: 10.1097/SLA.0b013e31814699a2.
13. Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J Vasc Surg 2005; 41(3): 423-435; discussion 435. DOI: 10.1016/j.jvs.2004.11.041.
14. Kudo T, Chandra FA, Kwun WH, Haas BT, Ahn SS. Changing pattern of surgical revascularization for critical limb ischemia over 12 years: endovascular vs. open bypass surgery. J Vasc Surg 2006; 44(2): 304-313. DOI: 10.1016/j.jvs.2006.03.040. (Pubitemid 44142917)
15. Bosiers M, Hart JP, Deloose K, Verbist J, Peeters P. Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia: experience with 443 infrapopliteal procedures. Vascular 2006; 14(2): 63-69. (Pubitemid 44047250)
16. Conrad MF, Kang J, Cambria RP, Brewster DC, Watkins MT, Kwolek CJ, et al. Infrapopliteal balloon angioplasty for the treatment of chronic occlusive disease. J Vasc Surg 2009; 50(4): 799-805.e4. DOI: 10.1016/j.jvs.2009.05.026.
17. Giles KA, Pomposelli FB, Hamdan AD, Blattman SB, Panossian H, Schermerhorn ML. Infrapopliteal angioplasty for critical limb ischemia: Relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs. J Vasc Surg 2008; 48(1): 128-136. DOI: 10.1016/j.jvs.2008.02.027.
18. Fernandez N, McEnaney R, Marone LK, Rhee RY, Leers S, Makaroun M, et al. Predictors of failure and success of tibial interventions for critical limb ischemia. J Vasc Surg 2010; 52(4): 834-842. DOI: 10.1016/j.jvs.2010.04.070.
19. Sadek M, Ellozy SH, Turnbull IC, Lookstein RA, Marin ML, Faries PL. Improved outcomes are associated with multilevel endovascular intervention involving the tibial vessels compared with isolated tibial intervention. J Vasc Surg 2009; 49(3): 638-644. DOI: 10.1016/j.jvs.2008.10.021.
20. Wang C, Hsieh I-C, Cherng W, Chen C, Tung T, Lee J, et al. Differentiation profile of peripheral blood-derived vascular progenitor cell predicts intimal hyperplasia after coronary stenting. Heart Vessels 2011: 1-10. DOI: 10.1007/s00380-011-0118-4.
21. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) Trial. J Am Coll Cardiol 2011; 57(11): 1264-1270. DOI: 10.1016/j.jacc.2010.10.035.
22. Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Christeas N, Kagadis GC. Infrapopliteal application of paclitaxel-eluting stents for critical limb ischemia: midterm angiographic and clinical results. J Vasc Interv Radiol 2007; 18(11): 1351-1361. DOI: 10.1016/j.jvir.2007.07.018. (Pubitemid 350010920)
23. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006; 92(5): 641-649. DOI: 10.1136/hrt.2005.061622.
24. Christiaans MH, Ernst JMPG, Suttorp MJ, van den Berg JC, Overtoom TTC, Kelder JC, et al. Restenosis after carotid angioplasty and stenting: a follow-up study with duplex ultrasonography. Eur J Vasc Endovasc2003; 26(2): 141-144. DOI: 10.1053/ejvs.2002.1974. (Pubitemid 36927206)
25. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology 2001; 221(1): 137-145. (Pubitemid 32880382)
26. Kim JS, Kang TS, Ahn CM, Ko YG, Choi D, Jang Y, et al. Efficacy of subintimal angioplasty/stent implantation for long, multisegmental lower limb occlusive lesions in patients unsuitable for surgery. J Endovasc Ther 2006; 13(4): 514-521. DOI: 10.1583/05-1798MR.1. (Pubitemid 44423045)
27. Desgranges P, Boufi M, Lapeyre M, Tarquini G, Van Laere O, Losy F, et al. Subintimal angioplasty: feasible and durable. Eur J Vasc Endovasc 2004; 28(2): 138-141. DOI: 10.1016/j.ejvs.2004.02.020. (Pubitemid 38967266)
28. Matoba S, Matsubara H. Therapeutic angiogenesis for peripheral artery diseases by autologous bone marrow cell transplantation. Curr Pharm Des 2009; 15(24): 2769-2777.
29. Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost 2010; 103(4): 696-709. DOI: 10.1160/TH09-10-0688.
30. Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg 2011; 53(2): 445-453. DOI: 10.1016/j.jvs.2010.08.060.
31. Fukuda D, Shimada K, Tanaka A, Kawarabayashi T, Yoshiyama M, Yoshikawa J. Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol 2004; 43(1): 18-23. DOI: 10.1016/j.jacc.2003.08.026. (Pubitemid 38045908)
32. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8(4): 403-409. DOI: 10.1038/nm0402-403. (Pubitemid 34407037)
33. Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest 2004; 113(9): 1258-1265. DOI: 10.1172/JCI19628. (Pubitemid 39069924)
34. Wang CH, Anderson N, Li SH, Szmitko PE, Cherng WJ, Fedak PW, et al. Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circ Res 2006; 99(6): 617-625. DOI: 10.1161/01.RES.0000243210.79654.fd. (Pubitemid 44401453)
35. Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T, et al. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation 2007; 115(5): 553-561. DOI: 10.1161/CIRCULATIONAHA.106.621714. (Pubitemid 46226164)
36. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005; 111(7): 926-931. DOI: 10.1161/01.CIR.0000155612.47040.17. (Pubitemid 40279896)
37. Berman JW, Kazimi M, Ma H. Development of the atherosclerotic plaque. In: Brown DL, ed. Cardiovascular Plaque Rupture. City: Marcel Dekker, 2002: 1-43.
38. Buemi M, Allegra A, Aloisi C, Corica F, Alonci A, Ruello A, et al. Cold pressor test raises serum concentrations of ICAM-1, VCAM-1, and E-Selectin in normotensive and hypertensive patients. Hypertension 1997; 30(4): 845-847. (Pubitemid 27441111)
39. Peter K, Nawroth P, Conradt C, Nordt T, Weiss T, Boehme M, et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17(3): 505-512. (Pubitemid 27133140)
40. Yasukawa H, Imaizumi T, Matsuoka H, Nakashima A, Morimatsu M. Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1. Circulation 1997; 95(6): 1515-1522. (Pubitemid 27142810)
41. Hayashi S, Watanabe N, Nakazawa K, Suzuki J, Tsushima K, Tamatani T, et al. Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries. Circulation 2000; 102(14): 1710-1717.
42. Shimazawa M, Kondo K, Hara H, Nakashima M, Umemura K. Sulfatides, L- and P-selectin ligands, exacerbate the intimal hyperplasia occurring after endothelial injury. Eur J Pharmacol 2005; 520(1-3): 118-126. DOI: 10.1016/j.ejphar.2005.06.039. (Pubitemid 41375819)
43. Riou S, Mees B, Esposito B, Merval R, Vilar J, Stengel D, et al. High Pressure promotes monocyte adhesion to the vascular wall. Circ Res 2007; 100(8): 1226-1233. DOI: 10.1161/01.RES.0000265231.59354.2c. (Pubitemid 46684136)
44. Mehrhof FB, Schmidt-Ullrich R, Dietz R, Scheidereit C. Regulation of vascular smooth muscle cell proliferation: Role of NF-{kappa} B revisited. Circ Res 2005; 96(9): 958-964. DOI: 10.1161/01.RES.0000166924.31219.49. (Pubitemid 40712795)
45. Bu DX, Erl W, de Martin R, Hansson GK, Yan ZQ. IKKbeta-dependent NF-kappaB pathway controls vascular inflammation and intimal hyperplasia. FASEB J 2005; 19(10): 1293-1295. DOI: 10.1096/fj.04-2645fje. (Pubitemid 41113727)
46. Shimazawa M, Watanabe S, Kondo K, Hara H, Nakashima M, Umemura K. Neutrophil accumulation promotes intimal hyperplasia after photochemically induced arterial injury in mice. Eur J Pharmacol 2005; 520(1-3): 156-163. DOI: 10.1016/j.ejphar.2005.07.031. (Pubitemid 41375824)
47. Foulds S, Galustian C, Mansfield AO, Schachter M. Transcription factor NF kappa B expression and postsurgical organ dysfunction. Ann Surg 2001; 233(1): 70-78. (Pubitemid 32042778)
48. Huang B, Dreyer T, Heidt M, Yu JCM, Philipp M, Hehrlein FW, et al. Insulin and local growth factor PDGF induce intimal hyperplasia in bypass graft culture models of saphenous vein and internal mammary artery. Eur J Cardio-Thorac Surg 2002; 21(6): 1002-1008. DOI: 10.1016/S1010-7940(02)00111-2.
49. Bhardwaj S, Roy H, Heikura T, Ylä-Herttuala S. VEGF-A, VEGF-D and VEGF-DdeltaNdeltaC induced intimal hyperplasia in carotid arteries. Eur J Clin Invest 2005; 35(11): 669-676. DOI: 10.1111/j.1365-2362.2005.01555.x. (Pubitemid 41640902)
50. Cheema AN, Hong T, Nili N, Segev A, Moffat JG, Lipson KE, et al. Adventitial microvessel formation after coronary stenting and the effects of SU11218, a tyrosine kinase inhibitor. J Am Coll Cardiol 2006; 47(5): 1067-1075. DOI: 10.1016/j.jacc.2005.08.076.
51. Kwon HM, Sangiorgi G, Ritman EL, Lerman A, McKenna C, Virmani R, et al. Adventitial vasa vasorum in balloon-injured coronary arteries: Visualization and quantitation by a microscopic three-dimensional computed tomography technique. J Am Coll Cardiol 1998; 32(7): 2072-2079. DOI: 10.1016/S0735-1097(98)00482-3. (Pubitemid 29010478)
52. Simons M. VEGF and restenosis: The rest of the story. Arterioscler Thromb Vasc Biol 2009; 29(4): 439-440. DOI: 10.1161/ATVBAHA.109.183970.
53. Xu X, Lu H, Lin H, Ni M, Sun H, Li C, et al. Lymphangiogenesis promotes inflammation and neointimal hyperplasia after adventitia removal in the rat carotid artery. Int J Cardiol 2009; 134(3): 426-427. DOI: 10.1016/j.ijcard.2007. 12.098.
54. Li Y, Zhang F, Nagai N, Tang Z, Zhang S, Scotney P, et al. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 2008; 118(3): 913-923. DOI: 10.1172/JCI33673. (Pubitemid 351364599)
55. Li X, Lee C, Tang Z, Zhang F, Arjunan P, Li Y, et al. VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr 2009; 3(4): 322-327.
56. Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010; 464(7290): 917-921. DOI: 10.1038/nature08945.
57. Stefanadis C, Toutouzas K, Stefanadi E, Lazaris A, Patsouris E, Kipshidze N. Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: An experimental study. Atherosclerosis 2007; 195(2): 269-276. DOI: 10.1016/j.atherosclerosis.2006.12.034. (Pubitemid 350087955)
58. Rzucidlo EM. Signaling pathways regulating vascular smooth muscle cell differentiation. Vascular 2009; 17(Suppl 1): S15-20.